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Abstract 
The embryonic myosin isoform is expressed 
during fetal development and rapidly down-
regulated after birth. Freeman-Sheldon Syndrome 
(FSS) is a disease associated with missense 
mutations in the motor domain of this myosin. It 
is the most severe form of distal arthrogryposis 
leading to over contraction of the hands, feet, and 
orofacial muscles, and other joints of the body. 
Availability of human embryonic muscle tissue 
has been a limiting factor in investigating the 
properties of this isoform and its mutations. Using 
a recombinant expression system we have studied 
homogeneous samples of human motors for the 
wild type (WT), and three of the most common 
FSS mutants: R672H, R672C, and T178I. Our 
data suggest that the WT embryonic myosin 
motor is similar in contractile speed to the slow 
type I/ȕ cardiac based on the rate constant for 
ADP release and ADP affinity for actin.myosin. 
All three FSS mutations show dramatic changes 
in kinetic properties, most notably, the slowing of 
the apparent ATP hydrolysis step (reduced 5-9 
fold) leading to a longer lived detached state and 
a slowed Vmax of the ATPase (2-35 fold), 
indicating a slower cycling time. These mutations 
therefore seriously disrupt myosin function.  
 
Introduction 
Autosomal dominant mutations in 5 of the 
10 human sarcomeric myosin heavy chain 
(MyHC) genes cause a wide variety of cardiac 
and skeletal myopathies (1); and new mutations 
continue to be discovered  (2-5). There are 2 
developmental myosin isoforms: MyHC-
perinatal (MYH8) and MyHC-embryonic 
(MYH3) both of which are expressed primarily 
during fetal development and during muscle 
regeneration (6).  
There have been few studies of developing 
muscle in humans, however, the order in which 
myosin isoforms are expressed has been 
described. Primary skeletal muscle fibers appear 
after 8 weeks of gestation followed at 10 weeks 
by the appearance of secondary fibers which 
become the predominant form by week 21 (7). 
Primary fibers express MyHC-emb and the 
cardiac or slow muscle isoform, MyHC-ȕ (8, 9), 
with the MyHC-emb being detected before 
MyHC-ȕ (10). Secondary fibres initially only 
express MyHC-emb followed by MyHC-peri 
(10). At week 15 MyHC-emb accounts for about 
81 % of all human MyHC transcripts (11), while 
a population of tertiary fibers emerges at week 16 
Freeman-Sheldon Syndrome mutation kinetics 
2 
 
that expresses adult fast myosin (9, 12). Adult 
myosins and tertiary fibres gradually increase 
towards the end of gestation (9, 10) as both 
MyHC-emb and MyHC-peri are downregulated 
with MyHC-emb and MyHC-peri only being 
faintly detectable in a few fibers in 1 month old 
infants. However, recently MyHC-emb protein 
has been detected outside this time window (13).  
Mutations in MyHC-emb cause autosomal 
dominant distal arthrogryposis (DA2A), the most 
severe form of which is Freeman-Sheldon 
Syndrome (FSS) (11). Phenotypes include club 
foot, camptodactyly (contractures of the fingers 
or toes), contractures of oral facial muscles 
leading to a ‘whistling face’ phenotype, and in the 
most severe cases, scoliosis (14). There are 
currently 8 identified MyHC mutations that cause 
FSS (14-16). 90% of FSS cases are linked to 3 
mutations in the motor domain of MyHC-emb: 
R672C, R672H and T178I (14).  Patients who 
have the T178I mutation have the most severe 
phenotypes (facial contractures and congenital 
scoliosis), R672H results in intermediate severity 
and R672C is the least severe (14). Adult muscle 
fibres from individuals with wild type MyHC-
emb and those with the R672C mutation do not 
differ in expression levels of MyHC-emb protein 
(13). Tajsharghi et al (2008) (17) presented data 
from a FSS patient with a T178M mutation in 
MYH3. At 15 months the individual had a higher 
level of MyHC-peri expression (>20% of all 
fibers) compared to that of 8 ‘healthy’ control 
samples (0 – 2% of all fibers) taken at a similar 
time of development (10-15 months). Samples 
taken from the same patient at 5 years showed a 
predominance of type-1/MyHC-ȕ expression 
with small, scattered type-1 fibers. This suggests 
that there could be a compensatory effect or a 
developmental defect which causes MyHC-peri 
to be expressed later or longer in postnatal 
development. Tajsharghi et al (2008) 
hypothesised that the myopathy occurs during 
embryonic development and that after birth, when 
MyHC-emb is downregulated, there is a recovery 
of the muscle leaving some residual muscle 
defects.  Functional studies on muscle fibers from 
healthy and FSS individuals with the R672C 
mutation showed that the mutant fibers had 
reduced force, prolonged relaxation time, and 
incomplete relaxation (13).  
Embryonic myosin heavy chain is the most 
abundant during development when muscles are 
being formed (6). Since distal muscles are more 
affected in FSS, it is interesting to note that distal 
muscles appear to be formed earlier during 
development than proximal muscles (18). They 
may therefore express embryonic myosin for a 
longer period of time than proximal muscles. 
To understand the pathogenesis of FSS, it is 
necessary to understand the nature of the defect in 
the mutant myosin motor proteins and how it 
might be corrected.  Both residues involved, T178 
and R672, are highly conserved in all myosin II 
molecules and located near the ATP binding site 
close to the P-loop where the Ȗ-phosphate of ATP 
binds (Figure 1). Examination of  homologous 
myosin motor domain structures (subfragment 1 
or S1; Figure 1a) shows that T178 is at the end of 
4th strand of the central 7 stranded ȕ-sheet and 
close to the ATP binding site at the base of the P-
loop (Figure 1b) in a location that can influence 
ATP binding and hydrolysis. R672 is located on 
the 3rd ȕ-strand with the side chain buried and 
which interacts with the relay helix, SH1-SH2 
domain and the ȕ-strands on either side, regions 
which go through major conformational changes 
during the myosin cross-bridge cycle (19, 20). 
Notably the crystal structures show an interaction 
between R672 and T178 which may account for 
the similar phenotypes in the mutants. 
Due to the difficulty of isolating 
homogeneous myosin samples from human 
muscle and the limited ability to obtain samples 
from FSS patients, we utilised an established 
recombinant expression approach (21). This 
approach was first used by Wang et al. (22) and 
we have used it to study the kinetics of all human 
adult skeletal and cardiac isoforms, and two 
mutations in the human cardiac MyHC-ȕ 
associated with hypertrophic cardiomyopathy 
(HCM) (23-25). These studies have demonstrated 
that this is a powerful technique for studying 
homogeneous, human, wild type and mutant 
myosin S1 samples using both biochemical 
kinetics and in vitro motility approaches. We used 
this recombinant approach to study pure human 
WT MyHC-emb and the 3 FSS-causing mutants. 
Although some results have been reported on 
embryonic and R672C mutant muscle fibres (11); 
(13), to our knowledge this is the first detailed 
functional study of purified WT MyHC-emb and 
any of the mutations that cause FSS. 
 
Methods 
Proteins – Human embryonic MyHC-S1 
proteins were expressed and purified as described 
previously Resnicow et al. 2010 (21). We 
constructed shuttle plasmids containing the S1 
coding region for MYH3 (Met1-Ser843) 
upstream of a 6x-Histidine tag. Using the 
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pAdEasy kit these plasmids were used to 
construct recombinant replication-deficient 
adenovirus that express MYH3. We first cloned 
the WT MYH3 gene and then performed site-
directed mutagenesis to produce the R672C, 
R672H and T178I mutations. The viral particles 
were amplified using HEK293 cells and the cell 
lysates were clarified using cesium chloride 
gradients and the concentrated virus was stored in 
a glycerol buffer at –20 °C. 
Infected C2C12 cells were incubated for 5 
days and frozen into a cell pellet. This was then 
homogenized in a low salt buffer, centrifuged and 
the supernatants purified by two procedures. For 
stopped-flow we used nickel affinity 
chromatography (HisTrap HP 1 ml column). 
Afterwards the S1 was dialysed into the low salt 
stopped-flow buffer (25 mM KCl, 20 mM MOPS, 
5 mM MgCl2, 1 mM DTT, pH 7.0, Figure 2). 
From between 1500-3000 cm3 of cultured C2C12 
cells we isolated 1-2 mg of purified MyHC with 
a concentration between 10-20 µM. A small 
amount of endogenous myosin persisted in the S1 
sample purified for stopped-flow. Using 
densitometry software (Scion Image) to analyse 
SDS-PAGE gels we calculated the contaminate 
myosin as < 5% of the S1 by mass; or 1:40 molar 
ratio of myosin: S1. It is possible that the myosin 
and S1 were bound to actin and so were co-
purified.  
For ATPase measurements the purification 
scheme was modified and extended. Nickel 
affinity chromatography was performed by 
gravity in Bio-Rad Econo-Pac column packed 
with HisPur Ni-NTA Resin. Eluates were 
dialyzed in a low-salt/low-imidazole buffer. The 
eluted material was subjected to anionic exchange 
chromatography (HiTrap HP 1 mL column) and 
desalted by another buffer exchange into the 
ATPase assay buffer (see ATPase method). This 
gave a higher purity of S1 necessary for ATPase 
assays. 
As previously reported (21) the recombinant 
S1 co-purifies with the endogenous mouse light 
chains (Figure 2). Essential light chains (ELC) 
MLC1A, MLC1F and regulatory light chain 
(RLC) MLC2F appear to purify with the 
recombinant S1 since their bands are much denser 
than the ELC MLC3F and in the correct ratio to 
the heavy chain. They are the same light chains 
that have been found to associate with embryonic 
myosin in tissue (26). The percentage identity 
between the human and mouse light chains are 
90-95%. Rabbit skeletal actin was prepared as 
previously described (Pardee & Spudich 1982) 
and labelled with pyrene at Cys-374 (Criddle 
1985). 
ATPase - For steady-state ATPase 
measurements we modified the NADH-coupled 
assay as described in (27). This assay system 
couples the ADP production to NADH oxidation 
to NAD+, therefore absorbance was read at 340 
nm. We used a 96-well format and the assay 
buffer used in all experiments was 12 mM PIPES, 
2 mM MgCl2, and 1 mM DTT at pH 6.8 and 25 
ºC. Bovine cardiac actin was purified as 
previously described (Pardee & Spudich) and 
used for ATPase measurements. Once thoroughly 
and rapidly mixed the assays was read for 30 min 
in a Molecular Devices SpectraMax to monitor 
absorbance over time. The Michaelis-Menten 
equation was fit to the data to determine the 
maximal activity (Vmax) and the associated actin 
constant for myosin (KM) using GraphPad Prism. 
Transient kinetics – All kinetic experiments 
were conducted in 20 mM MOPS buffer with 25 
mM KCl, 5 mM MgCl2, and 1 mM DTT , pH 7 at 
20 °C, unless otherwise indicated. Measurements 
were performed with a High-Tech Scientific SF-
61 DX2 stopped-flow system. The concentrations 
stated are those after mixing in the stopped-flow 
observation cell unless otherwise stated. All 
stopped-flow traces were analysed in either 
software provided by TgK Scientific (Kinetic 
Studios) or Origin (Microcal). Intrinsic 
tryptophan fluorescence was measured by 
excitation at 295 nm and observed through a 
WG320 filter. In the absence of actin the kinetics 
of S1 and ATP or ADP were interpreted using the 
seven-step model described by Bagshaw et al. 
(28) (Scheme 1), where the forward rate constants 
are k+i and the reverse rate constants are denoted 
k
-i. Ki = k+i/k-I representing the equilibrium 
constant at the ith step in the reaction.  
In the ADP displacement from S1 assays the 
two amplitudes are proportional to the 
concentration of S1 present as either free S1 or 
S1.ADP. ADP concentrations determine the 
amplitudes as follows: 
Aslow= Amax[ADP]K5+[ADP] + Amin (Eq. 1) 
Afast= AmaxK5[ADP]+ K5 + Amin (Eq. 2) 
When actin was present, the sample was 
excited at 365 nm, emission of pyrene-labelled 
actin was detected after being passed through a 
KV399 cut-off filter. The binding of S1 to pyrene-
labelled actin quenches the fluorescence therefore 
dissociation could be measured by an increase in 
fluorescence.  The interactions between acto.S1 
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and ATP or ADP were analysed based on the 
model in scheme 2 (23) 
Following a reversible binding of ATP to 
actomyosin there is a rate-limiting isomerisation 
(k’+2) of the complex leading to rapid actomyosin 
dissociation. ADP and ATP compete for the 
nucleotide binding site on the S1 and ADP 
binding is governed by the dissociation constant 
K’5 (=k’+5/k’-5). 
A dissociation reaction can be measured 
when the pyrene-labelled actin is in a complex 
with S1 since the complex quenches the pyrene 
signal. ATP induces the dissociation of S1 from 
actin resulting in an increase in fluorescence 
allowing the reaction kinetics to be determined. 
Using scheme 2, Eq. 3 can be used to determine 
the constants K’1k’+2, k’+2, and 1/K’1. 
kobs= K
'1k'+β[ATP]
1+ K'1[ATP]     (Eq. 3) 
Eq. 4 defines the kinetics when ATP and 
ADP are in rapid competition for binding to the 
actomyosin complex and that K’1 [ATP] < 1, such 
that the equation is linear with respect to [ATP]. 
kobs= K
'1k'+β[ATP]
1+[ADP]K'5     (Eq. 4) 
If in the absence of ADP the kobs = k0 then 
normalizing Eq. 4 can make different myosin 
isoform comparisons easier.  
krel= kobsk0 =
1
1+[ADP]K'5     (Eq. 5) 
To determine the actin affinity a S1 titration 
assay was performed as described by Kurzawa 
and Geeves (29). Fixing the concentration of 
pyrene-labelled actin the amplitude of the ATP 
induced dissociating reaction provides an 
estimate of the fraction of actin bound to S1 at 
increasing S1 concentrations. The amplitude 
dependence of S1 concentration was fitted to the 
physically significant root of the following 
quadratic equation. 
α= 
[M]+KD+[A]0- √([M]+ KD+ [A]0)β- 4[M][A]0
β[A]0
 (Eq. 6) 
In all cases, the data in the figures refer to 
individual experimental measurements, whereas 
Table 1 gives mean values of the fitted constant 
for a minimum of three separate measurements 
using different protein preparations. 
Sequence Alignments and Homology 
Modelling – Three-dimensional homology 
models were generated (Figure 1) for the human 
embryonic isoform using SWISS-MODEL 
automatic comparative protein modelling server 
(30-33). The primary sequence for the embryonic 
myosin was pairwise aligned with the sequence of 
the six scallop structures (PDB codes given 
below) using CLUSTAL OMEGA alignment 
protocol. These alignments were submitted to 
SWISS-MODEL which generated the models. 
The sequence identity between the human 
embryonic S1 sequence and the scallop myosin 
was 60% so allowed us to build well resolved 
structures. The scallop structures were used 
because they represent different conformational 
states of the cross-bridge cycle: post-rigor like 
structure with ADP bound (PDB code 2OTG), a 
rigor like structure without nucleotide bound 
(PDB code 2OS8), a post rigor structure without 
a nucleotide bound (PDB code 1SR6), a pre-
power stroke state containing ADP-VO4 (PDB 
code 1QVI), the actin-detached state containing 
ADP-BeFx (PDB code 1KK8), and a near rigor 
state with ADP bound (PDB code 1S5G).  We 
compared the interactions we found in the 
homology to the two MyHC-ȕ structures (4P7H 
and 4DB1, sequence identity 79%) to validate 
their existence in human myosin structures as 
well as the original scallop structures.   
 
Results 
Nucleotide binding to actin.S1 and actin 
binding to S1 
The detachment of the actin.myosin cross-
bridge is the step that is thought to limit 
shortening velocity in contracting muscle fibers. 
This can be limited by either the rate of ATP 
binding to the cross-bridge or the preceding ADP 
release step (Scheme 2). Since these are the first 
reports of detailed kinetics of wild type (WT) 
MyHC-emb, we will compare its properties to 
another slow myosin, the well-characterized 
MyHC-ȕ. For slow type myosins the affinity of 
ADP for actin.S1 is normally tighter than the fast 
type myosins (IIa, IIb, IIx, α) and ADP release 
limits the detachment and the overall muscle 
shortening velocity (34-36). Therefore we 
examined these steps first. 
ATP induced detachment from actin is 
slower for myosin S1 carrying FSS mutations – 
The ATP induced dissociation of S1 from actin 
was monitored by the fluorescence of a pyrene 
label covalently attached to Cys-374 of actin 
(Figure 3A). At low concentrations of ATP WT 
MyHC-emb, R672C and T178I are best described 
by a single exponential fit. At all ATP 
concentrations there is a second slower phase for 
R672H, which is best described by a double 
exponential fit. At high ATP concentrations 
([ATP] > 100 µM) T178I develops a slow second 
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phase, similar to the slow component in R672H. 
A slow component was not seen for the WT 
MyHC-emb or the R672C at any concentration of 
ATP used. At low ATP concentrations there is a 
linear relationship between kobs and ATP 
concentration for all constructs (Figure 3B) which 
gives a second order rate constant of actin 
dissociation (K’1k’+2, Table 1).  Compared to ȕ-
cardiac myosin S1, the WT MyHC-emb shows 
faster ATP-induced dissociation kinetics whereas 
for the FSS mutants this process is slower (Table 
1, see Figure 9). 
The maximum rate of ATP induced 
dissociation is significantly altered by the FSS 
mutations – Over larger ATP concentrations, the 
relationship between kobs and ATP concentration 
is best described by a hyperbola (Figure 3B) 
which gives a maximum rate constant of 
dissociation (k’+2) and the affinity of ATP binding 
in the initial step 1/K1. There is a second slow 
component found at all ATP concentrations for 
R672H and at the higher ATP concentration 
(>100 µM) for T178I. One cause of a slow 
component could be ADP contamination, 
therefore S1 was incubated with apyrase to 
hydrolyse any ADP; however this has no effect 
on the slow component for either the R672H or 
T178I. This led us to the hypothesis that the slow 
component is caused by a conformational change 
in the ATP binding pocket from a closed to open 
state (Kα, Scheme 2) previously seen in MyHC-ȕ 
(37) (Table 1). The maximum rate constant of 
opening from the closed conformation (k+α) is 
summarised in Table 1.  Using the ratios of the 
fluorescence amplitudes for both components it is 
possible to calculate the equilibrium constant of 
the conformational change (Kα, Table 1). 
ADP affinity (K’5) for WT MyHC-emb 
motor domain and the 3 mutations is typical of 
a slow myosin – To determine ADP affinity in the 
presence of actin, a competition assay was used 
(Figure 4A). The observed rate constant (kobs) 
reduces as ADP increases and exhibits a 
hyperbolic dependence on ADP concentration 
defining the ADP-affinity, K’5 (Figure 4B).  A 
similar measurement for T178I results in a value 
of K’5 which is not significantly different from 
that for WT MyHC-emb. The ADP affinity for 
WT MyHC-emb is about 2-fold weaker than  the 
WT ȕ-myosin S1. The FSS mutation T178I does 
not alter ADP affinity compared to WT MyHC-
emb.  
The hyperbolic dependence of kobs on ADP 
concentration, found for WT MyHC-emb and 
T178I, is consistent with the rate constant of ADP 
release being of the same order or faster than the 
rate constant for ATP binding (K1k+2[ATP]) 
under these conditions. This was confirmed by 
measuring the rate of ADP displacement directly 
by incubating the actin-S1 complexwith a much 
higher ADP concentration and displacing with 
several high ATP concentrations (see Figure 5) 
(37).  
This type of hyperbolic dependence on ADP 
concentration is not found for the other two 
mutations (R672H and R672C) which shows a 
biphasic transient (Figure 4C).  This is consistent 
with the rate constant for ADP release (k’+5) being 
slower than the rate constant for ATP binding. 
The fast phase results from ATP binding to the 
fraction of actin.S1 which is free of ADP while 
the slow phase arises from the fraction of myosin 
as actin.S1.ADP from which ADP must first 
dissociate before ATP can bind.  
For R672H the observed rate constant of the 
slower phase remains constant while the 
amplitude increases at increasing ADP 
concentration.  In contrast, the fast phase 
amplitude decreases while the observed rate 
constant also remains constant (Figure 4C). A 
similar behaviour was also seen for the R672C 
mutation. When the fast and slow phase 
amplitudes are plotted against ADP 
concentration, both could be described by a 
hyperbolic function (Figure 4D), giving an 
overall ADP affinity (K’5). Comparing these three 
FSS mutants to WT MyHC-emb, the ADP-
affinity of R672H is about 3-fold tighter whereas 
for R672C and T178I this parameter is not 
significantly affected (Table 1). 
FSS mutations reduce the affinity of actin 
for myosin S1 but increase actin affinity in the 
presence of ADP – By preincubating 30 nM 
pyrene-labelled actin (concentration before 
mixing) with varied S1 concentrations and then 
rapidly mixing with 20 µM ATP (concentration 
before mixing, Figure 5A) it is possible to 
determine actin affinity (KA, Figure 5B).  This 
measurement was repeated for the three FSS 
mutations.  R672C and T178I have a similar KA 
value as WT MyHC-emb, while R672H has an 
affinity almost 20-fold weaker compared to WT 
MyHC-emb (Table 1).  
This assay was repeated with a constant 
saturating ADP concentration (20x the K’5 value) 
preincubated with the acto-S1 mixture to 
determine the actin affinity in the presence of 
ADP (KDA).  The affinity of the WT MyHC-emb 
for actin weakens 250-fold (Figure 5C). All the 
mutants however have an affinity 2-4 fold tighter 
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than the WT (Table 1).   This measurement also 
gives an estimate of the ADP release rate constant 
(k’+5) where a saturating ADP concentration is 
displaced by a high ATP concentration and is 
independent of ATP concentration. This results in 
a single exponential, the kobs is therefore linked to 
the k+5 value. Neither R672C nor T178I have a 
significantly different ADP-release rate than WT 
MyHC-emb, whereas R672H has an almost 3-
fold slower ADP-release rate. The ADP-release 
rate for WT MyHC-emb is significantly slower 
compared to cardiac ȕ myosin (Table 1). 
Nucleotide binding to myosin S1 in the 
absence of actin 
In the absence of actin, ATP binding to 
myosin can be monitored by a change in the 
intrinsic tryptophan fluorescence. The 
fluorescence change is caused by structural 
changes induced by both ATP binding and the 
ATP hydrolysis step (Scheme 1 – steps 1-3). 
While the binding of ATP to myosin is not part of 
the working cross-bridge cycle, the hydrolysis 
step controls how long myosin remains detached 
from actin.   
The FSS mutations reduce the ATP-
binding and hydrolysis rates for MyHC-emb S1 
– The binding and hydrolysis of ATP by myosin 
was observed via the intrinsic fluorescence of S1.   
S1 at 100 nM was mixed with varying 
concentrations of ATP (Figure 6A).  
All three FSS mutants have significantly 
slower kobs values and smaller amplitudes than 
WT MyHC-emb. , and increasing the S1 
concentration does not increase the amplitude 
The second order rate constant of ATP-binding, 
K1k+2, was determined by varying the ATP 
concentration and plotting kobs as a function of 
ATP (Figure 6B). ATP-binding for WT MyHC-
emb is about 2-fold faster than for ȕ-myosin S1 
and all three mutants have significantly lower 
second order rate constants compared to WT 
MyHC-emb (Table 1).   The three FSS mutations 
strongly reduce ATP-binding to myosin S1 
compared to WT MyHC-emb. 
The maximum rate of ATP binding for WT 
MyHC-emb (kmax) was also determined from the 
hyperbolic fits (Fig 5B & Table 1). The value of 
kmax can either be attributed to the maximum rate 
of ATP binding (k+2) with switch 1 and switch 2 
closing or the hydrolysis step (k+3 + k-3), which 
will be addressed in the discussion.  
ADP-affinity is very tight for WT MyHC-
emb and R672C – The ADP affinity of myosin-
S1 can be measured by preincubating S1 with 
varying concentrations of ADP and rapidly 
mixing with excess ATP to displace the ADP. A 
two phase reaction is expected, consisting of a 
fast and a slow element representing the ATP 
binding to free S1 and ADP being displaced, 
respectively (Figure 6C).   Increasing the 
concentration of ADP does not alter the kobs for 
the fast or slow phase but does affect the 
amplitudes (Figure 6D) as more of the S1 is 
occupied by ADP that has to be displaced (slow 
phase) before ATP can bind. The measurement 
was repeated for each of the FSS mutations. 
However, the low fluorescence amplitudes 
observed on binding ATP made these 
measurements very difficult. The assay was only 
successful for R672C, and even then it was only 
possible to observe the loss of the fast phase. 
Using equation 5, the ADP-affinity (K5) could be 
determined, however is not significantly different 
from the WT MyHC-emb (Table1). ADP 
displacement could not be measured for R672H 
and T178I because the 2% amplitude observed on 
ATP binding is too small to measure.  Attempts 
to measure ADP binding using fluorescent 
nucleotides Mant- and Coumarin- modified ATP 
or ADP also result in no apparent change in 
fluorescence for R672H and T178I. 
The Vmax and KM values of the three FSS 
mutants are reduced – The ATPase activity of 
the WT MyHC-emb and the three FSS mutants 
was measured as described in the methods.    Both 
the values of Vmax and KM are significantly greater 
for WT than those for the mutants (Figure 7A). 
T178I data was plotted on a log [actin] scale 
(Figure 7B) to highlight that there is activation 
along with the increase in actin concentration. 
However the KM is so low and the Vmax so slow 
that this appears as a linear fit in Figure 7A. The 
values of Vmax and KM are summarised in Table 1 
along with the Vmax/KM.  
Homology models of the WT MyHC-emb 
and mutant motor domains show disrupted 
interactions between the ATP binding pocket 
and relay helix in the mutant proteins – We 
examined the local structural interaction of the 
two mutated residues R672 and T178 using 
embryonic homology models based on both 
scallop myosin II crystal structures These two 
residues are highly conserved throughout the 
myosin family and conserved in embryonic, 
cardiac and scallop myosin.  
  The homology models of WT MyHC-emb 
shows that residue R672 is buried in the core of 
the myosin molecule, located on the ȕγ strand of 
the central sheet. R672 interacts with residues on 
the two ȕ strands on either side (ȕβ and ȕ4) and 
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also with a residue located on the relay helix 
(F490). We will focus on two key interactions 
here whereas a more detailed summary of 
interactions can be found in Table 2A & B.  
One key interaction is the H-bond between 
R672 and residue T178. T178 is located on ȕ4 at 
the base of the P-loop which is involved in ATP 
binding and hydrolysis. This R672-T178 
interaction is found in all conformational states 
available for WT MyHC-emb, indicating this H-
bond is preserved as the myosin molecule goes 
through the cross-bridge cycle. For both the 
T178I and R672C mutations this hydrogen bond 
is lost in all myosin homology models whereas 
for the R672H mutant this H-bond remains 
present in the majority of the structures.  
Another key interaction is the π-cation bond 
between R672 and residue F490. F490 is located 
on the relay helix close to a bend in the helix 
which develops during the recovery stroke and 
recovers at some point during the power stroke. 
This interaction is present in all WT MyHC-emb 
homology models but found to be consistently 
lost in both R672H and R672C mutations 
throughout the cycle. From our modelling it is 
difficult to know if the loss of the hydrogen bond 
between the T178 and R672 in the T178I mutant 
results in disruption of the π-cation bond between 
R672 and F490.   
R672, located on the central ȕ-sheet, appears 
to facilitate interaction between the ȕ4 strand and 
the relay helix.  Note that T178 is at the end of the 
ȕ4 strand and is immediately adjacent to the P-
loop motif 179GESGAG184. This motif is one of 
three loops that bind to the Ȗ-Pi of ATP. Loss of 
coupling of P-loop movements to the relay helix 
by mutation to either R672 or T178 is expected to 
cause major disruption of the cross-bridge cycle. 
Discussion 
WT MyHC-emb has properties of a slow 
type myosin but differs significantly from the 
classic slow type myosin, MyHC-β – To our 
knowledge this is the first complete kinetic 
analysis of the human embryonic myosin S1 
isoform. Comparison of the kinetic properties of 
WT MyHC-emb to the slow WT MyHC-ȕ, see 
Table 1 and Figure 9, shows that there are 
significant differences between the two.   
The high affinity of ADP for actin.myosin 
(K’5 = 14 µM) and the slow rate constant for ADP 
release from actin.myosin (k’+5 = 22 s-1) are 
indicators of a slow type myosin (38). The slow 
ADP release would result in a relatively long 
lived A.M.D complex (lifetime 1/k’+5 = 45 ms 
versus 17 ms for MyHC-ȕ under these conditions) 
that has high affinity for actin (KDA = 0.53 µM) 
and therefore could hold tension against a load.  
The slow ADP release rate constant is likely to 
limit the maximum shortening velocity (Vo = d/τ 
= working stroke / attached life time) to 5-10 
nm/45 msec = 0.1-0.2 µm/sec. At the same time 
the ATPase Vmax is similar for the two WT 
isoforms (6.0 and 7.0 s-1) resulting in a higher 
unloaded duty ratio for the emb myosin (duty 
ratio = Vmax/k’+5 = 0.γγ) compared to the ȕ 
myosin (0.10). 
The second order rate constant for ATP 
binding to actin.S1 (K’1k’+2), is two-fold faster for 
MyHC-emb than for MyHC-ȕ. This is due to ATP 
affinity for actin.S1 (K’1) being almost 4-fold 
tighter (84 vs 327 µM) for emb-S1 while the 
maximum rate of actin dissociation (k’+2, 780 vs 
1500 s-1) is half that of MyHC- ȕ. This means that 
the detachment of actin is slower at saturating 
ATP but  much less sensitive to the concentration 
of ATP available than the MyHC-ȕ. This could be 
important as the MyHC-emb could maintain its 
activity  in fluctuating ATP concentrations. .  
The fluorescence change associated with 
ATP binding to MyHC-emb S1 in the absence of 
actin is twice that of ȕ-cardiac S1. The maximum 
kobs for this process at saturating ATP 
concentrations is also 30 % faster  and close to 
that expected for a fast muscle myosin. This 
fluorescence change has normally been assigned 
to the steps controlling ATP hydrolysis and the 
recovery stroke (k+3 + k-3). ADP binding gave less 
than half of the fluorescence change for ATP 
binding to MyHC-emb suggesting the signal does 
primarily result from the change in the local 
environment of the conserved tryptophan at the 
end of the relay helix that is known to report the 
recovery stroke and hydrolysis step (39, 40). ADP 
affinity in the absence of actin is almost 4 times 
tighter for MyHC-emb than MyHC-ȕ. However, 
in the presence of actin, the reverse is true. ADP 
affinity is almost 2-fold weaker for MyHC-emb. 
This results in a large increase in the 
thermodynamic coupling constant for ADP 
(K’5/K5), which increases almost 10-fold from 
11.5 for MyHC- ȕ to 95 for MyHC-emb.  Thus, 
actin is much more effective at displacing ADP 
for MyHC-emb than for MyHC-ȕ.  
In summary, our data are consistent with 
MyHC-emb myosin being a slow type motor with 
a high nucleotide affinity as recently described by 
Racca et al (11). Our data also show that ATP 
binding (K’1k’+2) is 2-fold faster than MyHC-ȕ, 
which is suggestive of a fast type myosins (41). 
However, the ADP release rate (k’+5) is almost 3 
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times slower than MyHC-ȕ which is indicative of 
a slow type myosin. Therefore MyHC-emb 
properties sit between the fast and slow type 
myosins. 
The three FSS mutations significantly slow 
the cross-bridge cycle speed and alter the 
balance of the cycle at various steps – The Vmax 
for the ATPase cycle is reduced substantially (2 
to 30 fold) for all three mutations with at least 10 
fold increases in the apparent affinity of actin 
(Km).  The rate constant for ADP release (limiting 
cross-bridge detachment) is little changed for 
T178I and R672C but reduced to 1/3rd for the 
R672H mutant.  This results in estimates of the 
duty ratio (= k’+5/Vmax) being reduced in each case 
from 0.3 for WT MyHC-emb to ~0.18 for the two 
R672 mutations and very low for T178I (0.008). 
The two R672 mutations myosins would be able 
to sustain a lower force than the WT MyHC-emb 
and T178I would be very ineffective as a force 
holding myosin – consistent with this mutation 
having the most severe phenotype (11). 
The major differences between the WT 
MyHC-emb and the three mutations in the cross-
bridge cycle are ATP induced dissociation of 
actin from actin.S1 (K’1k’+2), ATP binding to S1 
(K1k+2) and ATP hydrolysis (k+2 or k+3 + k-3) (see 
Table 1 and Figure 9). The results suggest that 
ATP binding is slower than for WT MyHC-emb 
for all three mutations, by a factor 2 – 5 for actin 
S1 (K’1k’+2) and by 5- to 30-fold for S1 alone 
(K1k+2).   The slowed rate constant for ATP 
binding is unlikely to have any physiological 
affect because the ATP in the cell is maintained 
at > 1 mM and each construct would be expected 
to bind ATP within 1 msec. The maximum rate 
constant of actin dissociation is, however, 
reduced 2- to 3-fold for the two R672 mutations 
and this would result in a longer lived A.M 
complex (2-3 msec).   
One of the most striking changes is the 
reduction of k+3 + k-3 by 5-10 fold. If this 
represents the ATP hydrolysis step then this 
would be a significant slowing of the ATPase 
cycle leading to the myosin spending more time 
detached from actin in each ATPase cycle. This is 
highlighted in comparing the rate constant of the 
hydrolysis step (k+3 + k-3) with the Vmax of the 
ATPase.  For WT MyHC-emb the hydrolysis rate 
constant is more than 20 times the value of Vmax 
while it is reduced to 10 and 7 for fold for the two 
R672 mutations.   
A second point of interest is actin affinity 
with and without ADP present. In the absence of 
ADP, the actin affinities (KA) of the three mutants 
are significantly reduced compared to the WT 
MyHC-emb. However, since the experiments 
were conducted with 30 nM pyrene-labelled actin 
and the KA values are less than 10 nM (except for 
R672H), we can only conclude that the affinities 
are very tight and may even be the same. We can, 
however, say that the affinity of R672H for actin 
is significantly reduced; almost 20-fold weaker. 
The affinity in the presence of ADP (KDA), on the 
other hand is 1.5- to 4-fold tighter for all three 
mutants compared to the WT MyHC-emb. The 
only significant difference between the three 
mutants for ADP affinity in the presence of actin 
was the R672H where K5 was 3-fold tighter.  
From these data (Table 1) it is clear that all 
three of the mutations have significant kinetic 
differences compared to the WT MyHC-emb. 
The common difference between the three is the 
reduced apparent rate of ATP hydrolysis. 
The interaction between R672 and the relay 
helix is lost for the FSS mutants– This 
investigation was limited by the lack of 
tryptophan fluorescence change on ADP binding 
in the three mutants.  Homology models for each 
mutation suggest a possible explanation for this 
loss of fluorescence. R672 and F490 (on the relay 
helix) form a π-cation bond, which is lost with the 
two R672 mutations. R672H has the potential to 
form π-π bonds (42) but none were observed in 
the homology models. These π-cation interactions 
form between positive ions or protein residues 
and the π face of a benzene ring or other aromatic 
structure (43). These interactions can be as strong 
as or even stronger than salt bridges, so a 
complete loss of such a contact could have a large 
effect on the protein. During the ATPase cycle the 
C terminus of the relay helix bends away from the 
ȕ-sheet, with the tryptophan immediately after the 
relay helix reporting a change in fluorescence as 
it moves. Homology models for the rigor-like 
conformation of myosin (PDB code 2OS8) and 
the pre-power stroke conformation (PDB code 
1QVI) revealed that F490 is located just before 
the point in the relay helix where it bends as part 
of the power stroke/recovery stroke (Figure 8A).  
F490 is one of three phenylalanines (Figure 8b) 
that had previously been identified as part of a 
fulcrum on the relay helix in myosin S1 (44). This 
work also showed that F489  and F490  sandwich 
F670  forming the fulcrum  which stays locked 
together through the whole transition. It is 
possible that the π-cation bond between R672 and 
F490 plays a structural role in holding the fulcrum 
together and maintaining  contact with the ȕ sheet 
in which R672 sits.  
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Complete loss of this interaction in both 
R672 mutations could  disrupt the structure of the 
fulcrum making it less stable. This  translates into 
the loss of amplitude in the tryptophan 
fluorescence signal. , which indicates the relay 
helix is not moving properly in the recovery 
stroke and a slowing of the hydrolysis step linked 
to the recovery stroke. This complements the 
findings that the specific force of the R672C was 
reduced (13) as the conformational changes in the 
ATP and actin binding domains are not efficiently 
relayed to the converter domain and neck region.  
A second important interaction is the 
hydrogen bond between R672 and T178. In the 
two mutations, R672C and T178I, this hydrogen 
bond is completely lost and is partially lost in the 
R672H. Destabilisation of this region is the 
probable cause for the reduction in the k+2 or k+3 
+ k
-3 step seen for all three mutations. Therefore 
this bond between R672 and T178 must have 
some structural importance bringing the residues 
required for hydrolysis into proximity with the 
ATP. The loss of this bond could account for the 
reduction in the ATP hydrolysis rate. The 
reduction in tryptophan fluorescence in the T178I 
mutant also suggests that the bond between R672 
and T178 is having an indirect effect on the π-
cation bond from R672 to the relay helix.  
The FSS mutations slow down the 
dissociation rate and once detached spend 
longer not bound to actin, leading to a longer 
ATPase cycle time – Our data support the finding 
that a longer, slower rate of relaxation as seen for 
FSS mutants (?) could be explained by a reduced 
detachment event (13). There was a 2-5 fold 
reduction in the second order rate constant for 
detachment (K’1k’+2) for the three mutations. 
However the reduction in the ATP hydrolysis step 
we have seen is a novel observation for the three 
FSS mutations. It is most likely that the 
destabilising effect of the mutations on the P-loop 
are having a detrimental effect on ATP binding 
and ATP hydrolysis. Furthermore, the loss of 
interactions between the central ȕ sheet and the 
relay helix may hamper conformational changes 
within the molecule leading to the actin 
dissociation step. Both would lead to a longer 
cycling time where the myosin is bound to actin 
for longer or delayed in hydrolysing ATP. This 
would leave the myosin mainly in the M.T or 
A.M.T state, increasing the ATPase cycle time.  
As the major myosin isoform expressed in 
embryonic development the effects of the mutant 
alleles of embryonic myosin should manifest 
themselves during the formation of skeletal 
muscle and its earliest function.  Just as with most 
myosin based myopathies, the vast majority of 
reported cases of FSS are heterozygous; the 
prediction being that homozygous individuals 
would be inviable. It is noteworthy that FSS, a 
form of distal arthrogryposis, affects muscles in 
the lower legs and forearms, which appear to 
develop early relative to proximal skeletal muscle 
in fetal development (18). The timing and 
abundant expression of the mutant isoform during 
this stage could explain the symptoms seen post-
birth; at a time when the expression of embryonic 
myosin has decreased significantly. Consistent 
with the joint contracture phenotype, these FSS 
mutations display severely reduced rate constants 
for cross-bridge detachment and slower cycling 
times. Understanding how the mutant myosin 
influences muscle contraction at different levels 
of expression along with the WT MyHC-emb 
myosin, or an up regulation of other myosins, 
would be important to determine. We are 
currently developing models to allow the 
behavior of different myosin isoforms in a 
sarcomere to be predicted (45, 46). 
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Table 1: Transient kinetic parameters measured for wild type beta and embryonic, R672H, R672C, 
and T178I myosin S1 mutations. The values represent the mean ± SEM based on a minimum of 
three different protein preparations. All measurements were performed at 20 °C in 25 mM KCl, 20 
mM MOPS, 5 mM MgCl2, 1 mM DTT (pH 7) unless stated otherwise. Shaded boxes show the values 
that have changed significantly. 
 
*KCl concentration 0 mM  
a Nag et al in same ionic strength as this experiment obtained from C2C12 cells. 
b
 p < 0.05 determined by Student’s t test as compared to wild type embryonic-S1. 
c
 p < 0.01 determined by Student’s t test as compared to wild type embryonic-S1. 
d
 p < 0.001 determined by Student’s t test as compared to wild type embryonic-S1. 
Rate Constant Wild Type β  a Wild type Emb Emb R672H Emb R672C Emb T178I
K1k+2 (µM
-1
 s
-1
) 5.8 ± 0.4 
b 12.5 ± 1.9 0.4 ± 0.04 
d
1.1 ± 0.07 
d
2.3 ± 0.1 
c
1/K1 (µM) 15.9 ± 1.4 10.9 ± 2.0 34.4 ± 5.0 
b
23.6 ± 2.6 
b 7.7 ± 0.6
k+2 or k+3 + k-3 (s
-1
) 91.2 ± 1.8
 d 130 ± 3.4 14.3 ± 0.5 
d
25.4 ± 1.3 
d
17.7 ± 0.6 
d
K5 (µM) 0.53 ± 0.07 
b 0.15 ± 0.018 - 0.2 ± 0.04 -
k+5 (s
-1
) 0.63 ± 0.03 
b 0.89 ± 0.07 - - -
K'1k'+2 (µM
-1
 s
-1
) 4.4 ± 0.2 
b 9.4 ± 1.0 4.5 ± 0.3 
c
2.2 ± 0.5 
d
3.3 ± 0.2 
d
1/K'1 (µM) 327.9 ± 53.3 
b 84.3 ± 9.7 92.3 ± 9 120 ± 19.3 317.7 ± 41.1 
c
k'+2 (s
-1
) 1543 ± 100 
b 777.7 ± 16.8 413 ± 32.2 
d
261 ± 8.4 
d
1033.2 ± 60.2 
b
Kα 4.1 ± 1.4 - 4.4 ± 0.8 - 6.9 ± 1
k+α (s
-1
) 153.4 ± 10.6 - 31.5 ± 2.5 - 66.1 ± 9.1 
K'5 (µM) 6.1 ± 0.3 
b 14.3 ± 1.9 4.8 ± 0.5 
c 18.1 ± 1.7 12.4 ± 2.2
k'+5 (s
-1
) 58.7 ± 1.7 
d 22.0 ± 1.8 7.4 ± 0.2 
d 18.6 ± 1.1 25.7 ± 0.5
KA (nM) 10 ± 1.8 
b 2.1 ± 0.2 40.2 ± 2.1 
d
7.2 ± 1.2 
b
4.8 ± 0.2 
d
KDA (nM) 109.3 ± 24.1 
d 526 ± 60.3 366.7 ± 31 331.3 ± 68.6 123.5 ± 15.1 
d
KDA/KA 10.9 250 9 46 25.7
K'5/K5 11.5 95 - 90.5 -
Vmax (s
-1
) 6.0 ± 0.5 7.0 ± 0.15 1.3 ± 0.05 
d
3.5 ± 0.05 
d
0.2 ± 0.008 
d
KM (µM) 40 ± 6 38.5 ± 2.4 3.7 ± 0.7 
c
4.6 ± 0.3 
d
0.67 ± 0.16 
d
Vmax/KM (s
-1
 µM
-1
) 0.15 0.18 0.35 0.76 0.30
ATP binding to S1
ATPase *
ADP binding to S1
ATP binding to acto-S1
ADP binding to acto-S1
S1 affinity for actin
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Table 2a. Full list of interactions between R672 in WT MyHC-emb and the two R672 mutants.  
There are interactions between R67β, on ȕγ, and C1βγ and T1β5, on ȕβ of the central ȕ sheet in most 
conformations. The exception being the contact to C123 in the near rigor, ADP-bound state (PDB 
1S5G). These interactions are predicted to be conserved in the R67βC and R67βH mutations. A π-
cation bond that exists between R67β and F1ββ (ȕβ) in the rigor state (βOS8) and is lost in both 
mutations but a novelπ-π bond is formed between R67βH and F1ββ in the rigor state (2OS8). The 
hydrogen bond between R67β and L176 (ȕ1) is also lost in both mutations in the rigor state. T178 (on 
ȕ4) hydrogen bonds to R67β in each structure; however, this interaction is lost in the post-rigor 
(1SR6) and the detached (1KK8) states for R672H and are lost completely for R672C. A second 
significant loss of interaction is the π-cation bond between R672 and F490 on the relay helix, which is 
non-existent in either mutation. A π-cation bond to F670 is lost for both mutations in the detached 
state, however a π-π bond is formed in the pre-power state (1QVI).  A hydrogen bond between V671 
is present in WT MyHC-emb in the rigor and post rigor states (1OS8, 2OTG, and 1SR6) but lost in 
both mutations. The hydrogen bond between N697 on the SH1-SH2 domain is conserved in all three 
models in the rear rigor ADP-bound state (1S5G). However this is lost in R672H in the detached state 
(1KK8) and in R672C, in the post-rigor state (1SR6). Interestingly, this interaction is formed in both 
mutants in the rigor (1KK8) and post-rigor (2OTG) states.  
Interaction present in wt
Interaction present in R672H
Interaction present in R672C
No interaction
R672 interactions 2OTG 2OS8 1SR6 1QVI 1KK8 1S5G
Residue 
(Scallop/Homology)
Location Interaction
post-rigor 
(ADP)
rigor post-rigor pre-power detached
near rigor 
ADP-
F119/F122 βϮ π-Đation/π-π 
bond
C120/C123 βϮ H-bond (main 
chain)
A122/T125 βϮ H-bond (main 
chain)
L173/L176 βϰ H-bond (side 
chain)
T175/T178 βϰ H-bond (side 
chain)
F488/F490 Relay helix
π-Đation ďond
F667/F670 βϯ π-Đation/π-π 
bond
V668/V671 βϯ H-bond (side 
chain)
N694/N697 SH1-SH2
H-bond (side 
chain)
PDB
Freeman-Sheldon Syndrome mutation kinetics 
16 
 
Table 2b: Full list of interactions between T178 in WT MyHC-emb and T178I. The only change in 
the T178I mutation is the complete loss of the hydrogen bond between T178 and R672. The other two 
interactions between V671 and C67γ (both on ȕγ) are both intact (except V671 in the post-rigor state – 
2OTG, which is not present in WT MyHC-emb or T178I). 
 
 
 
 
Interaction present in wt
Interaction present in T178I
No interaction
T178I 2OTG 2OS8 1SR6 1QVI 1KK8 1S5G
Residue 
(Scallop/Homology)
Location Interaction post-rigor 
(ADP)
rigor post-rigor pre-power detached near rigor 
ADP-bound
V668/V671 βϯ H-bond (main 
chain)
R669/R672 βϯ H-bond (side 
chain)
C670/C673 βϯ H-bond (main 
chain)
PDB
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Figure 1: Homology model of embryonic myosin S1. This ribbon structure is based on the scallop 
structure in the pre-power stroke conformation (PDB code: 1QVI). (A) The myosin heavy chain is 
shown in grey, the SH1-SH2 helices are shown in orange; the relay helix in yellow, the P-loop in purple, 
and the 7 stranded ȕ sheet in red. Arginine 672 (R672) and Threonine 178 (T178) residues are shown 
in green and blue space filling mode respectively. Both of these residues are highly conserved across 
species and myosin-II isoforms including the scallop myosin and human MyHC-emb. Both residues are 
in the centre of the S1 domain located in the upper 50K domain near the ATP binding cleft. (B) Blow 
up of the region around R672 (located on the 3rd ȕ strand) and T178 on the 4th ȕ strand of the 7 stranded 
ȕ-sheet that runs through the S1 domain. T178 is also at the base of the P-loop (GESGAG residue no.) 
which is involved in ATP binding. The green dotted lines represent hydrogen bonds which can be seen 
between T178 and R67β, while the solid orange line indicates a π-cation bond that can be seen between 
R672 and F490. The interactions of R672 and T178 are summarised in Table 2. Residues not labelled 
are those found to interact with either R672, T178 or both and are summarised in Tables 2A/B. 
 
Figure 2: SDS-PAGE gel of purified wild type embryonic S1. The myosin S1 co-purifies with a 
small amount of endogenous mouse full length myosin (<5% by weight) and the four mouse light 
chains; three major bands MLC2F (regulatory), MLC1F, and MLC1A (both essential) and a minor band 
of MLC3F. The three major bands have been identified in embryonic S1 (Bottinelli & Reggiani, 1996) 
suggesting that the fourth (?) light chain (MLC3F) is binding to the endogenous myosin.  
 
Figure 3: ATP induced dissociation of embryonic S1 from pyrene labelled actin. (A) Traces of 50 
nM WT emb-S1, and the three mutants pre-incubated with equimolar pyrene-labelled actin then  rapidly 
mixed with 10 µM ATP. Each trace has been normalised and offset by the previous one by  0.2% 
fluorescence. At low [ATP] WT MyHC-emb, R672C, and T178I were best described by a single 
exponential fit resulting in a kobs = 70 s-1 (amp = 27%), 12 s-1 (amp = 46%), 24 s-1 (amp = 45%) for WT 
MyHC-emb, R672C, and T178I respectively. At high [ATP] the T178I mutation was best described by 
a double exponential, while R672H was best described by a double exponential at all [ATP] resulting 
in a fast and slow phase giving kobs = 36 s-1 (amp = 32%) and kobs = 4.4 s-1 (amp = 3.8%) respectively. 
(B) The dependence of kobs on [ATP] yielded K’1k’+2 = 8.5 µM-1 s-1, 5.2 µM-1 s-1, 1.8 µM-1 s-1, and 3.1 
µM-1 s-1 for WT MyHC-emb (black filled squares), R672H (red filled circles), R672C (green filled 
triangles), and T178I (blue filled diamonds). The maximum rate yielded a k’+2 = 806 s-1 for WT MyHC-
emb , 439 s-1 and 36 s-1 for the R672H fast and slow (red open circles) phases respectively, 262 s-1 for 
R672C, and 1007 s-1 and 49 s-1 for the T178I fast and slow (blue open diamonds) phases respectively. 
Values given here are that of a single assay.  
 
Figure 4: ADP affinity for pyrene-labelled actin.S1. (A) Fluorescent traces of 50 nM pyrene-labelled 
actin pre-incubated with 50 nM WT MyHC-emb and increasing [ADP] (0-400 µM) rapidly mixed with 
10 µM ATP. As the [ADP] increased the kobs decreased from 72 s-1 to 3 s-1. (B) The dependence of kobs 
on [ADP] for WT MyHC-emb (squares) and T178I (circles) resulting in a K’5 = 16 ± 1.5 µM and 17 ± 
4 µM respectively.  (C) Traces of 50 nM pyrene-actin pre-incubated with 50 nM R672H S1 and 
increasing [ADP] (0-40 µM) rapidly mixed with 30 µM ATP. Since there was a consistent slow phase 
even at low [ATP] the rates stayed constant while the amplitude of the fast phase decreased from 26% 
to 6%, the slow phase amplitude increased from 3.5% to 21%. This behaviour was also seen in the 
R67βC mutation.  (D) The dependence of fluorescence amplitude of [ADP] for R67βH results in a K’5 
= β.6 ± 1.1 µM for the fast phase and K’5 = 5 ± 1.3 µM for the slow phase. 
 
Figure 5: Embryonic S1 affinity for actin in the absence and presence of ADP. (A) Traces of 
increasing concentrations (0 µM to 120 nM) of WT MyHC-emb  pre-incubated with 30 nM pyrene-
labelled actin then rapidly mixed with 10 µM ATP. Over a concentration series the fluorescence 
amplitude increased with [S1]. (B) The dependence of amplitude on [S1] can be described by a quadratic 
function (Eq. 6) giving a KA value of 2.5 nM for WT MyHC-emb  (filled squares), 43 nM for R672H 
(open squares), 6.1 nM for R672C (filled circles), and 5.2 nM for T178I (open circles). (C) Repeating 
the same experiment but this time incubating the acto.S1 with saturating [ADP]. Plotting the amplitude 
against the [S1] again gives a quadratic dependence which in turn gives a KDA value of 706 nM for WT 
MyHC-emb  (filled squares), 306 nM for R672H (open squares), 386 nM for R672C (filled circles), 
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and 71 nM for T178I (open circles). Concentrations of S1 are before mixing.Add panel D here with 
ADP release exp data 
 
Figure 6: Nucleotide binding to embryonic S1. (A) Tryptophan fluorescence changes observed on 
rapidly mixing 50 µM ATP with 100 nM WT MyHC-emb and for the three mutants S1s.  All four were 
best described with a single exponential fit yielding kobs = 102 s-1 (amplitude = 6.6%), 7.3 s-1 (amplitude 
= 1.6%), 12 s-1 (amplitude = 3.5%), 18 s-1 (amplitude = 1.4%) for WT MyHC-emb, R672H, R672C, 
and T178I respectively. The single exponential fits are shown with solid black lines. (B) The hyperbolic 
dependence of kobs on [ATP] yielded K1k+2 = 8.8 µM-1 s-1, 0.3 µM-1 s-1, 0.95 µM-1 s-1, and 2.1 µM-1 s-1 
for WT MyHC-emb (filled squares), R672H (open squares), R672C (filled circles), and T178I (open 
circles) respectively. The maximum rate gives a value of kmax = 134 s-1 for WT MyHC-emb, 15.2 s-1 for 
R672H, 25 s-1 for R672C, and 17.8 s-1 for T178I. (C) The protein fluorescence observed after mixing 
0.1 µM WT MyHC-emb pre-incubated with 50 nM ADP with 50 µM ATP. The data could be best 
described by a double exponential function with a fast phase (kobs = 92 s-1 and amp = 5.9%) and a slow 
phase (kobs = 1 s-1 and amp = 1.3%). (D) The dependence of the amplitudes of the fast and slow phases 
on [ADP] was hyperbolic resulting in a KD = 0.13 ± 0.06 µM for the fast phase (filled squares) and KD 
= 0.12 ± 0.03 µM for the slow phase (open squares). This measurement was not possible with the R672H 
or T178I mutations while there was only one phase for the R672C. 
 
Figure 7: ATPase assays of the WT MyHC-emb and the three FSS mutations. (A) The actin 
activation of the S1 ATPases with best fit Michaelis-Menten curves superimposed on the data points. 
These fits gave a Vmax = 7.0 s-1 for WT MyHC-emb and a KM = 38.5 µM (filled squares). The R672H 
(filled circles) had a Vmax = 1.3 s-1 and a KM = 3.7 µM, R672C (open squares) a Vmax = 3.5 s-1 and a KM 
= 4.6 µM, and T178I (open circles) a Vmax = 0.2 s-1 and a KM = 0.7 µM. (B) The ATPase assay of the 
T178I mutant on a log time scale to highlight the T178I fit to a Michaelis-Menten function despite a 
small activation by actin. Results plotted are from two protein preps with 3-4 technical replicates each 
time. 
 
Figure 8: Homology model of WT MyHC- emb showing the relay helix, R672 and F122, F490, 
and F670 in rigor and pre-power stroke. (A) Structure based on scallop structure (PDB code: 2OS8) 
where the motor domain is in the rigor conformation and the relay helix is straight (Blue). There is a 
single π-cation bond between R672 and F490 shown in orange.  A superimposed second relay helix (in 
red) is based on scallop structure in the pre-power stroke conformation (PBB code: 1QVI). The relay 
helix is bent just after F490 and the π-cation interaction between R672 and F490 remains.  (B) R672 
(blue), F489 (orange), F490 (green), and F670 (red) are shown with the relay helix to illustrate the 
phenylalanine residues acting as pivot point for the relay helix bend. R67β’s proximity and interactions 
with the F490 possibly anchor the helix allowing it to bend.  
 
Figure 9: Percentage changes in the rate and equilibrium constants of WT MyHC-emb compared 
to WT MyHC-β (A & B) and the three FSS mutations compared to WT MyHC-emb (C & D). (A 
& C) Equilibrium constants are defined in M units; a positive percentage means an increase in affinity 
while a negative indicates a weakening of affinity. (B & D) The rate constants are define in units of s-
1 or M-1s-1 and a positive percentage indicates a faster rate constant while a negative percentage, a 
slower rate constant. ns = not significant, * = p<0.05, ** = p<0.01, *** = p<0.001. 
 
Scheme 1: Seven step scheme of ATP binding to myosin 
 
Scheme 2: ATP or ADP binding to actomyosin leading to the dissociation of myosin from actin. 
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